We are live on ! Find out more
ALSV

ATP Life Science Ventures Portfolio holdings

AUM $898M
1-Year Est. Return 84.86%
This Fund
S&P 500
This Quarter Est. Return
+36.43%
1 Year Est. Return
+84.86%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$742M
AUM Growth
+$215M
Cap. Flow
+$14.5M
Cap. Flow %
1.96%
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$14.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
1
Stoke Therapeutics
STOK
$1.82B
$562M 75.8%
16,786,713
– –
AKRO
2
DELISTED
Akero Therapeutics
AKRO
$180M 24.2%
5,830,203
+415,000
+8% +$14.5M

Similar funds

TNB
TCF National Bank Sioux Falls, South Dakota $883M AUM 60.21% 1-Year Est. Return
FIB
First Interstate Bancsystem Billings, Montana $841M AUM
NAM
North American Management Boston, Massachusetts $738M AUM 49.23% 1-Year Est. Return
SGMP
Spark Growth Management Partners Boston, Massachusetts $591M AUM
FBP
Flippin Bruce & Porter Lynchburg, Virginia $553M AUM 70.43% 1-Year Est. Return
PA
Paracle Advisors Mercer Island, Washington $551M AUM 50.34% 1-Year Est. Return
AAM
Anglepoint Asset Management George Town, Cayman Islands $1.28B AUM 131.9% 1-Year Est. Return
PPCM
Pillar Pacific Capital Management Pacifica, California $1.29B AUM 80.18% 1-Year Est. Return

ATP Life Science Ventures's Q3 2020 Portfolio in Review

As of Q3 2020, ATP Life Science Ventures held 2 positions worth $742M, up 41% from $527M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2020: portfolio turnover was 0%. ATP Life Science Ventures opened no new positions and made no exits, leaving the 2-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ATP Life Science Ventures added most to Akero Therapeutics in Q3 2020, an estimated $14.5M increase.
  • ATP Life Science Ventures's ten largest holdings make up 100% of its $742M portfolio in Q3 2020.
  • ATP Life Science Ventures opened 0 new positions and closed 0 in Q3 2020.
  • ATP Life Science Ventures's portfolio value rose 41% quarter-over-quarter to $742M.

Based on ATP Life Science Ventures's 13F filing for Q3 2020, filed 6 Nov 2020.